Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URC102 Phase 2 in Gout
NCT02290210Phase 2Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epaminurad in gout, hyperuricemia, sponsored by JW Pharmaceutical Corporation. Started Jul 2014; status: completed.
02
Drugs
epaminurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02290210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02290210.